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Abstract: Preeclampsia is a potentially serious complication of pregnancy with increasing 
significance worldwide. Preeclampsia is the cause of 9%–26% of global maternal mortality and 
a significant proportion of preterm delivery, and maternal and neonatal morbidity. Incidence is 
increasing in keeping with the increase in obesity, maternal age, and women with medical comor-
bidities entering pregnancy. Recent developments in the understanding of the pathophysiology 
of preeclampsia have opened new avenues for prevention, screening, and management of this 
condition. In addition it is known that preeclampsia is a risk factor for cardiovascular disease 
in both the mother and the child and presents an opportunity for early preventative measures. 
New tools for early detection, prevention, and management of preeclampsia have the potential 
to revolutionize practice in the coming years. This review presents the current best practice in 
diagnosis and management of preeclampsia and the hypertensive disorders of pregnancy.
Keywords: preeclampsia, eclampsia, gestational hypertension, blood pressure, pregnancy 
screening, management, treatment, outcome
Epidemiology
Preeclampsia is a global health problem of increasing significance.1,2 Preeclampsia 
complicates 2%–8% of all pregnancies, contributes to 15% of preterm deliveries, and 
between 9% and 26% of maternal deaths worldwide.3 In the most recent confidential 
inquiry into maternal mortality in the UK, 22 of 107 direct maternal deaths from 2006 
to 2008 were related to preeclampsia and eclampsia.4
The incidence of preeclampsia is increasing with the global increase in maternal age, 
obesity, assisted reproductive techniques, and medical comorbidities that predispose to 
preeclampsia, such as diabetes, hypertension, and renal disease. Preeclampsia is more 
common in Afro-Caribbean women, multifetal gestation, and primigravidas.5
Although in simple terms, preeclampsia is understood to arise from failure of the 
normal development of the maternal–fetal interface in the placenta,6–8 the pathogen-
esis of the disease is not well established. Rapid advances in understanding in recent 
decades have opened up new avenues of exploration in screening for and prevention 
of preeclampsia, with the potential of significantly improving outcomes in the future. 
It is now clear that the onset of the disease is multifactorial, and interventions for 
prevention and management of preeclampsia will necessarily have to address a wide 
range of factors through lifestyle and diet modification and multidisciplinary care.
Preeclampsia is a risk to health not only in the immediate peripartum period – 
women who have suffered from preeclampsia are at increased risk of cardiovas-
cular disease throughout life,9–12 and children born from pregnancies affected by 
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 preeclampsia are more likely to suffer from metabolic 
syndrome, cardiovascular disease, and hypertension at earlier 
ages.13  Optimizing management of hypertensive disorders 
in pregnancy is a major step toward improving population 
health worldwide.
Hypertensive disorders in 
pregnancy
Hypertensive disorders of pregnancy can be subclassified into 
four groups – chronic hypertension, gestational hypertension, 
preeclampsia, and superimposed preeclampsia in the setting 
of chronic hypertension, as laid out in the ACOG (American 
Congress of Obstetricians and Gynecologists) guideline.14 
The International Society for the Study of Hypertension in 
Pregnancy (ISSHP) has published guidelines on diagnosis to 
establish global unity of meaning in referring to the various 
hypertensive disorders of pregnancy, with the most recent 
guidance being released in 2014. They include an additional 
category of white coat hypertension.15
Although each condition increases the risk of maternal 
and neonatal morbidity, the greatest risks are associated 
with a diagnosis of preeclampsia, either de novo or in the 
setting of chronic hypertension.16,17 The diagnostic criteria 
for these disorders vary somewhat among published inter-
national guidelines, particularly between the research and 
clinical setting, in the discrimination between preeclampsia 
and gestational hypertension, and in setting the definition of 
severe preeclampsia.14,15,18–20
Diagnostic criteria
Hypertension
Hypertension in pregnancy is defined as a blood pressure of 
greater than or equal to 140 mmHg (systolic) or 90 mmHg 
(diastolic) on at least two measurements, ideally separated by 
a period of rest.15 Severe hypertension is defined as a blood 
pressure of greater than 160–170/110 mmHg. Systolic hyper-
tension of greater than 180 mmHg is a medical emergency.
The gold standard for measurement is a mercury sphyg-
momanometer;21 however these are increasingly being 
withdrawn from clinical use for health and safety reasons. 
Aneroid devices require regular calibration, the interval for 
which can be increased by using wall or trolley mounted 
devices that are less susceptible to loss of accuracy. If an 
automated device is used, it should have been validated for 
use in pregnancy.
Blood pressure should be measured with the woman at 
rest and the arm held at the level of the heart. If the woman 
is supine she should be in the left lateral position.22 An 
appropriately sized cuff should always be used, with thigh 
cuffs used for women with arm circumferences greater than 
41 cm. In pregnancy, diastolic pressure is measured at the 
5th Korotkoff sound.
Proteinuria
Proteinuria is best measured using a 24-hour urine collec-
tion, although even this test is susceptible to user error.23 
A simultaneous 24-hour creatinine excretion measurement 
may assess the quality of the collection and aid in inter-
preting the results. Proteinuria is defined as total protein 
of .300 mg/day in the 24-hour collection. In practical 
terms, the delay inherent in obtaining a result makes this 
test suboptimal for facilitating rapid decision making about 
the need for delivery or admission in women with suspected 
preeclampsia.
A spot protein creatinine ratio (PCR) can be performed 
quickly on a single urine sample and provides a more rapid 
result that can facilitate efficient clinical management. 
A value greater than or equal to 30 mg/mmol is taken to 
indicate significant proteinuria.23 A negative test has a high 
negative predictive value, but a positive test should always, 
in ideal circumstances, be followed up by a 24-hour urine 
collection, particularly if the PCR is in the nephrotic range 
(.230 mg/mmol).23
Often in clinical practice, neither a 24-hour urine collec-
tion nor a spot PCR is available, and clinical management 
may be based on dipstick assessment for proteinuria. It is 
reasonable to initiate management of preeclampsia based 
on significant proteinuria on dipstick (.2+) when clini-
cal suspicion is strong and no recourse to other testing is 
 available. Caution should always be exercised in women 
where preeclampsia is strongly suspected with a negative 
urine dip because the sensitivity of dipstick testing is poor 
(negative predictive ratio 0.6),23 and many cases would be 
missed if relying on dipstick testing alone.
Women who present with proteinuria without hyperten-
sion should be monitored for development of preeclampsia 
or other renal disease, but not treated as preeclamptic. As 
many as 51% of women presenting with proteinuria with-
out hypertension will go on to develop preeclampsia in the 
remainder of pregnancy.24
The hypertensive disorders  
of pregnancy
Pre-pregnancy hypertension
Any woman presenting at booking with hypertension may 
have preexisting hypertension. Many apparently healthy 
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women will not have accessed health care prior to booking in 
pregnancy, and hypertension may be a new finding at booking 
in the first trimester.
Blood pressure should be recorded either pre-pregnancy 
or in early pregnancy, before the nadir in blood pressure 
in the second trimester. A normal blood pressure may be 
recorded between 16 and 20 weeks, even in a woman with 
chronic hypertension, because of the systemic vasodilation 
in pregnancy, which may cause diagnostic uncertainty later 
in pregnancy when hypertension is detected for the first 
time if no earlier blood pressure is noted. In this situation it 
is best to manage as gestational hypertension and consider 
further investigations for an alternative underlying cause if 
the hypertension does not resolve after pregnancy.
These women require careful evaluation to rule out 
hypertension secondary to other underlying pathology before 
declaring them to have essential hypertension. In addition, 
“white coat hypertension” is recognized in pregnant women 
and, while not entirely benign, does not carry the same 
risks as true essential hypertension. Whereas as many as 
22%–25% of women with chronic hypertension will develop 
preeclampsia in pregnancy, around half of all women with 
white coat hypertension will develop gestational hypertension 
and 8% will develop preeclampsia.25 A 24-hour ambulatory 
monitoring may be indicated to confirm the diagnosis prior 
to commencing antihypertensive therapy.24
Other women will have established chronic hypertension 
and may present in early pregnancy, already maintained 
on antihypertensive therapy. Ideally, women with existing 
hypertension should receive pre-conception counseling and 
stabilization on antihypertensive therapy appropriate for 
use in pregnancy. Women with chronic hypertension should 
receive early referral to an obstetric medicine service for 
the management of their pregnancy, as they are at increased 
risk of preeclampsia in pregnancy. According to the National 
Institute for Health and Care Excellence (NICE) guidance, 
these women should be offered low-dose aspirin from 
12 weeks of gestation.18
Gestational hypertension
Hypertension detected for the first time after 20 weeks 
of pregnancy and in the absence of any other features of 
preeclampsia is classified as gestational hypertension. It is 
therefore necessary to perform an assessment for protei-
nuria, laboratory tests for organ dysfunction, and consider 
ultrasound assessment of fetal growth in all women pre-
senting with asymptomatic new onset hypertension after 
20 weeks.
There is a risk of progression to preeclampsia of around 
25%,15 and women with gestational hypertension require 
monitoring throughout pregnancy. Hypertension carries a risk 
of cerebral hemorrhage, and the absence of proteinuria is not 
a reason to relax the treatment goals in controlling hyperten-
sion in pregnancy. These women are also at increased risk of 
future cardiovascular disease and may benefit from lifestyle 
and dietary advice to promote cardiovascular health.
Preeclampsia
The classical definition of preeclampsia has been new onset 
hypertension in pregnancy after 20 weeks with proteinuria 
(bearing in mind for both preeclampsia and gestational 
hypertension that the presentation may occur postpartum). 
As a disease with a highly diverse phenotypic spectrum, 
there are a number of presentations and there are inevitably 
patients who do not fit neatly into the classical definition. It 
can be particularly challenging in the setting of preexisting 
hypertension and/or renal disease to detect new onset preec-
lampsia; however, these women are those at highest risk of 
developing preeclampsia and its complications.
The most common presentation of preeclampsia is hyper-
tension, detected at a routine antenatal visit in an asymptom-
atic woman. The common symptoms of preeclampsia may 
present late and, in the mild forms, overlap to some degree 
with normal pregnancy – epigastric pain, nausea and vomit-
ing, peripheral and facial edema, headache with or without 
visual scotomas, and blurred vision. On examination, patients 
may be hyperreflexic with marked clonus, show an altered 
mental status, and have right upper quadrant tenderness on 
palpation. Most of these signs and symptoms will be present 
only in severe disease, and rapidly evolving symptoms should 
raise concern about impending severe disease.
Many patients clearly have a preeclampsia-like syndrome 
with similar prognosis and outcomes but have either no 
hypertension or no proteinuria. New onset hypertension may 
be combined with fetal growth restriction or development of 
hemolysis, elevated liver enzymes and low platelet (HELLP) 
syndrome, or eclampsia without proteinuria. Eclampsia 
may present with no previously documented hypertension 
or symptoms,26 although women will usually be found to be 
hypertensive after admission with seizures. At the present 
time, all guidelines in use require hypertension in order to 
diagnose preeclampsia.14,15,18–20
The ISSHP has recently elected to exclude proteinuria 
as a necessary condition to be met to establish the clinical 
diagnosis of preeclampsia in the presence of other maternal 
organ dysfunction or uteroplacental dysfunction.15 In a 
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research setting, to ensure specificity in included cases, it 
may be appropriate to maintain a requirement for proteinuria 
to be established. Older guidelines27 include proteinuria as a 
necessary condition for the diagnosis of preeclampsia, but it 
is vital to recognize the breadth of presentation of this disease 
and not dismiss, for example, a severely hypertensive woman 
with marked intrauterine fetal growth restriction as having 
gestational hypertension. Most expert bodies now follow the 
ISSHP in defining preeclampsia as hypertension and any of 
proteinuria, organ dysfunction, or fetal growth restriction 
consistent with placental insufficiency.
Preeclampsia superimposed on 
preexisting hypertension
Hypertension alone is not sufficient to diagnose preeclamp-
sia, and a rise in blood pressure and subsequent requirement 
for antihypertensive therapy in the third trimester is to be 
expected in women with essential hypertension. If women 
develop worsening hypertension in combination with either 
proteinuria, new organ dysfunction, or uteroplacental dys-
function, then preeclampsia may be diagnosed. In those 
women with long-standing hypertension and renal dysfunc-
tion, the diagnosis of preeclampsia is most problematic.
Severe preeclampsia
Most guidelines also include a subset of criteria to define 
those women with the most severe disease which can be used 
to target higher levels of medical and midwifery care at the 
patients most in need. Table 1 illustrates the criteria set for 
severe preeclampsia in several national guidelines.
Table 1 Diagnostic criteria of severe preeclampsia
National Institute for Clinical  
Excellence (2010) 
(any of the features below in  
combination with hypertension  
and proteinuria)
American College of Obstetricians  
and Gynecologists (2013) 
(any of the below with known  
preeclampsia)
American Society of 
Hypertension (2008)
Symptoms Headache 
visual disturbance 
vomiting 
epigastric pain
Severe persistent right upper  
quadrant or epigastric pain 
Cerebral or visual disturbance
Headache 
visual disturbance 
Abdominal pain
Signs Papilloedema 
Clonus 
Liver tenderness
Pulmonary edema Oliguria 
early onset disease (,35 weeks) 
Nonreassuring fetal monitoring
Hypertension Severe hypertension and  
proteinuria alone
Systolic BP .160 mmHg 
Diastolic BP .110 mmHg (on two occasions  
.4 h apart while on bed rest)
Diastolic .110 mmHg
Other maternal  
disorders
HeLLP syndrome 
Platelets ,100×109/L 
AST or ALT .70
Platelets ,100×109/L 
Liver enzymes . twice normal concentration 
Progressive renal insufficiency
elevated creatinine 
Nephrotic range proteinuria 
elevated AST or LDH
Abbreviations: HeLLP, hemolysis, elevated liver enzymes and low platelets; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase.
Early onset preeclampsia is used as a marker of severity, 
which is appropriate given the greatly increased risk of mater-
nal morbidity in pregnancies complicated by preeclampsia 
remote from term. The ACOG defines early onset as ,35 
weeks14 whereas the SOGC (Society of Obstetricians and 
Gynaecologists of Canada) uses ,34 weeks.19
There is also disagreement about whether systolic 
hypertension of greater than 160 mmHg (SOGC/American 
Society of Hypertension [ASH]) or 170 mmHg (Royal 
 College of Obstetricians and Gynaecologists [RCOG], 
Society of  Obstetric Medicine of Australia and New Zealand 
[SOMANZ]) is the most appropriate limit for severe hyper-
tension, but all agree that severe hypertension is a marker of 
severe preeclampsia.
The degree of proteinuria has, in the past, been included 
as a marker of severe disease. However, it is evident that 
simply the degree of proteinuria is not related to disease 
progression or outcomes. It is relevant to clinical manage-
ment when proteinuria in the nephrotic range is detected, 
which should alert clinicians to a further risk of venous 
thromboembolism (VTE). It should be noted that preec-
lampsia itself increases the risk of VTE, particularly if 
associated with a period of bed rest or hospital admission, 
and appropriate thromboprophylaxis should be prescribed. 
The degree of proteinuria should not influence the timing of 
delivery or the decision to start antihypertensive treatment 
or magnesium sulfate.28
Severe disease can develop rapidly, even in women 
previously classified as having “mild” disease. Worsening 
symptoms of abdominal pain, nausea and vomiting, and 
 
In
te
gr
at
ed
 B
lo
od
 P
re
ss
ur
e 
Co
nt
ro
l d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
82
.5
0.
2 
on
 2
2-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
integrated Blood Pressure Control 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
83
Current practice for management of hypertensive disorders in pregnancy
headache, while nonspecific, should always be taken seriously 
in a patient with known preeclampsia.18
Complications of hypertensive 
disorders of pregnancy
Preeclampsia is a multisystem disorder characterized by 
generalized endothelial damage, which can result in wide-
spread end-organ damage. The presence of any of these 
features is a marker of severe disease, even with relatively 
mild  hypertension. Of the maternal deaths attributable to 
preeclampsia in the last UK confidential inquiry, most were 
related to cerebral or hepatic complications. Two women died 
of ARDS (Acute respiratory distress syndrome).4 Table 2 
summarizes the complications associated with preeclampsia 
by organ system.
HeLLP syndrome
HELLP syndrome describes a constellation of Hemolysis 
(anemia with blood film evidence of  hemolysis), Elevated 
Liver enzymes showing hepatic dysfunction (transaminitis 
greater than twice the normal range), and Low Platelets 
(platelet count of less than 150,000/dL).3
HELLP occurs in around 5% of preeclampsia cases27 or 
10%–20% of severe preeclampsia, and is associated with 
1.1% maternal mortality and severe morbidity including dis-
seminated intravascular coagulopathy, liver hematoma, liver 
failure, and renal failure.29 Perinatal mortality rate is reported 
at 6%–17%.30,31 An initial minor derangement in transaminases 
and platelets can deteriorate rapidly, and blood tests should be 
repeated every 6–12 hours if the trend is worsening and the 
decision has been made to prolong pregnancy to allow adminis-
tration of corticosteroids for fetal lung maturity. Corticosteroids 
are not currently used to attempt to treat HELLP syndrome.18 
HELLP is, by definition, a marker of severe disease and requires 
multidisciplinary care, including hematology, renal, and hepatic 
physicians, and anesthetic involvement.
Renal impairment
Renal perfusion and filtration increase in normal pregnancy, 
and creatinine levels should therefore be lower than normal 
Table 2 Complications of preeclampsia by organ system
Cardiorespiratory Neurological Renal Hepatic Hematological
ARDS eclampsia Acute tubular necrosis Periportal inflammation Thrombocytopenia
Pulmonary edema Cerebral thrombosis or  
hemorrhage
Acute kidney injury Hepatic dysfunction DiC
Cardiomyopathy PReS Glomerular endotheliosis Hepatic hematoma/rupture Microangiopathic hemolysis
Generalized edema Altered mental status Acute fatty liver of pregnancy venous thromboembolism
Abbreviations: ARDS, adult respiratory distress syndrome; DiC, disseminated intravascular coagulopathy; PReS, posterior reversible leukoencephalopathy syndrome.
in pregnancy.32 Creatinine level over 90 µmol/L is a marker 
of severe disease, or sufficient evidence of organ dysfunction 
to diagnose preeclampsia in the presence of hypertension 
even without proteinuria.15
The glomerular endothelium may be directly damaged 
in preeclampsia, with a pathological finding of glomerular 
endotheliosis. In addition, the state of relative intravascular 
volume constriction can predispose to acute kidney injury. 
Renal impairment usually resolves with treatment of the 
preeclampsia. However, it may be worsened by the practice of 
fluid restriction in management of severe preeclampsia, and 
renal physicians should be involved where there is coexisting 
renal injury and pulmonary edema.
Pulmonary edema
Hypoalbuminemia leads to reduced oncotic pressure and rela-
tive intravascular volume depletion with significant interstitial 
fluid.33 Women with preeclampsia are thus much more vulner-
able to pulmonary edema, especially those with significant 
renal impairment. For this reason, careful fluid management 
is critical in all women with preeclampsia, and pulmonary 
edema secondary to iatrogenic fluid overload is a cause of 
maternal mortality in preeclampsia. It is common practice to 
restrict fluid intake in women with severe preeclampsia, but in 
the setting of concomitant renal injury, specialist nephrology 
advice may be required. Invasive monitoring in the setting 
of an intensive care unit is most appropriate for women with 
signs of pulmonary edema in preeclampsia.
eclampsia/cerebral hemorrhage
The most feared complications of preeclampsia are cerebral. 
They were the cause of mortality in 14 of the 22 maternal 
deaths reported by the Centre for Maternal and Child Enqui-
ries (CMACE) in the triennium 2006–20084 and account 
for 10% of severe maternal morbidity.26 Of the 14 maternal 
deaths, 5 were secondary to eclampsia and 9 secondary to 
intracranial hemorrhage.
Eclampsia literally means lightning, and it is the rapid-
ity of the onset that is so concerning. Eclampsia refers to 
generalized tonic–clonic seizures in a pregnant or recently 
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delivered woman with no other attributable cause, and 
complicates 1%–2% of severe preeclampsia.26 Search for an 
underlying cause should never delay initiation of treatment 
for eclampsia, and all generalized seizures in pregnancy after 
20 weeks should be managed as eclampsia unless a clear 
alternate cause (head trauma or known epilepsy) is identified. 
Seizures can arise with no or minimal preceding symptoms 
and signs, or in a woman who has had stable “mild” disease 
for several weeks. The most common preceding symptoms 
are severe headache, visual disturbance, and nausea, and 
may be present in 79% of cases who go on to present with 
eclampsia. Eclampsia may be 10–30 times more common in 
developing countries, largely because of differences in the 
quality of antenatal monitoring.1
Cerebral damage is caused by a failure of autoregulation 
related to endothelial damage, exacerbated by acute or large 
changes in the blood pressure. A common finding in eclamp-
sia is posterior reversible leukoencephalopathy syndrome 
(PRES),34 vasogenic edema in the posterior cerebral circula-
tion, a finding also seen in hypertensive encephalopathy. The 
hypertension associated with eclampsia and PRES is often 
less severe than in nonpregnant hypertensive encephalopathy, 
and it is possible that the endothelial damage associated with 
preeclampsia predisposes to this syndrome even at lower 
blood pressure.33
Differential diagnosis of 
preeclampsia
In a woman presenting with hypertension and any form of 
organ dysfunction, preeclampsia will always be the most 
likely differential diagnosis. However, many other conditions 
with microangiopathic effects can mimic elements of the 
preeclampsia phenotype. The management of these disorders 
may be different from that of preeclampsia, and misdiagnosis 
can have serious implications. For example, preterm delivery 
is not indicated in thrombotic thrombocytopenic purpura 
(TTP), and delivery of a fetus in a woman presenting at 
28 weeks will create major risk for the fetus without confer-
ring benefit on the mother. In addition, platelet transfusion 
in TTP carries a high risk of microvascular thrombosis and 
should be reserved for life-threatening bleeding.
The diagnostic challenge can be complicated by the pos-
sibility of preeclampsia coexisting with another disorder such 
as systemic lupus erythematosus.
Table 3 summarizes a range of conditions that can pres-
ent with some of the features of preeclampsia. Acute fatty 
liver of pregnancy, thrombotic thrombocytopenic purpura, 
Table 3 Differential diagnoses in severe preeclampsia by organ 
system
vasculature
 Pheochromocytoma
 Hyperaldosteronism
 Cushing’s disease
 Thyrotoxicosis
 Aorta coarctation
Renal system
 Lupus nephritis
 Acute and chronic glomerulonephritis
 interstitial nephritis
 Pyelonephritis
Liver
 Acute fatty liver of pregnancy
 Pregnancy cholestasis
 Hyperemesis gravidarum
 Cholecystitis
 Cholangitis
 viral hepatitis
 Acute pancreatitis
 Gastritis
 Gastric ulcer
Hemostasis
 Benign thrombocytopenia of pregnancy
 Thrombotic thrombocytopenic purpura
 Hemolytic uremic syndrome
 idiopathic thrombocytopenic purpura
 Antiphospholipid syndrome
 Folate deficiency
 Systemic lupus erythematosus
 Septic or hemorrhagic shock
Respiratory system
 Pneumonia
 Pulmonary embolus
 (Catastrophic) antiphospholipid syndrome
Cardiovascular system
 Peripartum cardiomyopathy
 Myocardial infarction or ischemia
Brain
 Cerebral systemic lupus erythematosus
 epilepsy
 Brain tumour
 Cerebrovascular accident
 Hypertensive encephalopathy
 Metabolic disease
eyes
 Retinal arterial or venous thrombosis
 Retinal ischemia
 Retinal detachment
 Persistent spasm of retinal vessels
 Central serous retinopathy
 Uveal melanoma
 Choroidal osteoma
Note: Reprinted from The Lancet, 376(9741), Steegers eA, von Dadelszen P, Duvekot JJ, 
Pijnenborg R, Pre-eclampsia, 631–644, Copyright © 2010, with permission from 
elsevier.3
 
In
te
gr
at
ed
 B
lo
od
 P
re
ss
ur
e 
Co
nt
ro
l d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
82
.5
0.
2 
on
 2
2-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
integrated Blood Pressure Control 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
85
Current practice for management of hypertensive disorders in pregnancy
hemolytic uremic syndrome and systemic lupus erythemato-
sus are those microangiopathic diseases where the laboratory 
test results and clinical presentation may overlap so closely 
with severe preeclampsia as to be extremely challenging to 
definitively diagnose.
There are some additional symptoms and laboratory 
f indings that may help to discriminate between these 
 conditions – for example, acute fatty liver of pregnancy 
(AFLP) is associated with hypoglycemia, ammonemia, and 
jaundice in 50%–100% of cases.35
Patients with suspected systemic lupus erythematosus 
should be tested for antinuclear or anti-dsDNA antibodies. 
Systemic lupus erythematosus patients who are also positive for 
antiphospholipid antibodies are at higher risk of microthrom-
botic events that can precipitate a clinical syndrome very similar 
to preeclampsia/HELLP. Serum complement levels may help 
determine if symptoms relate to a flare in disease activity.
Hemolysis and anemia are more common in TTP and 
hemolytic uremic syndrome (HUS), and von Willebrand 
factor multimers are more commonly elevated than in either 
AFLP or HELLP. The underlying pathology of TTP relates 
to a reduced activity of von Willebrand cleaving protease 
(a disintegrin and metalloproteinase with a thrombospon-
din type 1 motif, member 13, also called ADAMTS13) 
which is detectable on testing. However, this test may not 
be available in standard hospital laboratories. Antibodies 
against ADAMTS13 are also detectable and the titers may 
determine whether management is by plasma exchange, 
immunosuppression, or splenectomy.
New diagnostic markers
New diagnostic tests are under evaluation to address some 
of the inadequacies in current tests and obscurities in 
presentation. Urinary albumin/creatinine ratios are routinely 
used outside of pregnancy to detect proteinuria, and may be 
superior to PCR, but have yet to be validated in pregnancy 
and preeclampsia.19 Other markers investigated include 
pregnancy-associated plasma protein A (PAPP-A), placental 
protein 13 (PP-13), homocysteine, asymmetric dimethy-
larginine (ADMA), uric acid, and leptin. None of these has 
adequate performance individually as a clinical test, but 
several groups have proposed models that include a number 
of factors in addition to maternal history and/or ultrasound 
markers to identify women at risk of preeclampsia.36
As the pathogenesis of preeclampsia relates to an imbal-
ance in the control of angiogenesis, a number of factors 
might be outside the normal range in the weeks leading 
up to presentation with preeclampsia. Placental growth 
factor (PIGF) is a proangiogenic factor, and from as early 
as 11–13 weeks’ gestation low levels are associated with 
the later  development of preeclampsia.37 sFlt-1 (soluble 
fms-like tyrosine kinase 1) is antiangiogenic and levels 
are elevated as much as 5 weeks prior to the clinical onset 
of disease.38 Both have been evaluated as diagnostic tests 
but neither has sufficient sensitivity to be of use in clinical 
practice.  Preliminary studies have evaluated the use of the 
sFlt-1/PIGF ratio as a diagnostic and screening test, and 
have found a high specificity and sensitivity, particularly 
for early onset disease.39 Subsequent investigations have 
shown that it may be possible to discriminate between the 
hypertensive disorders of pregnancy with this ratio.40 This 
approach provides the possibility of rapid testing to clarify 
a diagnosis of preeclampsia, but requires further testing and 
validation with larger numbers of patients.
Screening for preeclampsia
Preeclampsia is a serious disease and it is likely that early 
identification of those at risk would allow targeted surveil-
lance and intervention, in order to improve the pregnancy 
outcomes for both mother and fetus. Low dose aspirin started 
in the first trimester in high risk women may reduce the risk 
of preeclampsia by up to 50%41 and may improve associated 
fetal and maternal outcomes.42 No other agents tested (proges-
terone or Vitamins D and E) have shown a reduction in risk 
of preeclampsia.43 Calcium supplementation reduces the risk 
only in women who are deficient in dietary calcium.44
With the introduction of aspirin as a prophylactic agent 
there is a package of intervention – aspirin and increased 
ultrasound and blood pressure monitoring – that can reduce 
the risk of preeclampsia and increase the chances of early 
detection in women determined to be at high risk. Now it is 
necessary to refine how we define who is at high risk.
Historically, screening took the form of regular blood 
pressure and urine checks throughout pregnancy for all 
women. In the UK today, NICE recommends using mater-
nal history, age, body mass index, and number of fetuses to 
select women for treatment with aspirin.18 Unfortunately, for 
a population prevalence of 4% the positive predictive value of 
this model is low and would lead to nearly half of all women 
being screen positive.5 With a sensitivity of only 77%, a sig-
nificant number of women who will develop preeclampsia are 
not detected with this model, so routine antenatal care still 
has to include regular blood pressure monitoring throughout 
later pregnancy. The maternal risk factors for preeclampsia 
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according to NICE, the World Health Organization (WHO), 
ACOG, and the SOGC are listed in Table 4.
A number of areas are under investigation and many show 
limited promise, but no single test can accurately predict 
preeclampsia, and most have poor positive predictive values. 
The strategy most commonly used is to identify a number of 
factors and combine these in a predictive model.
Abnormal uterine artery Dopplers at 20–22 weeks are 
strongly associated with risk of preeclampsia and intrauter-
ine growth restriction and are in current use to identify high 
risk women for additional monitoring in later pregnancy. 
However, to obtain maximal benefit from aspirin treatment, 
a first trimester screening tool is needed, and although first 
trimester uterine artery Dopplers are associated with risk of 
later preeclampsia, this test in isolation is not sufficiently 
sensitive for use in directing aspirin therapy and later preg-
nancy monitoring.36
A stepwise approach where women are identified as high 
risk in the first trimester and then reevaluated at the time of 
the mid-trimester anomaly scan is promising in terms of pick-
ing up most cases of early onset preeclampsia.45 Combining 
first trimester uterine artery Doppler findings with maternal 
characteristics and serum markers in the manner of the first 
trimester fetal anomaly screening is likely to provide the 
best approach to first trimester screening for preeclampsia. 
No models have yet been successfully validated in clinical 
practice, but such research is urgently required.
Antenatal care of women with 
preeclampsia
Once preeclampsia has been diagnosed, subsequent manage-
ment will be determined largely by gestation at presenta-
tion and markers of severity. The cure for preeclampsia is 
simple – delivery of the placenta will ultimately lead to 
Table 4 Maternal risk factors for preeclampsia according to NiCe, wHO, ACOG, and the SOGC
NICE (2010)18 WHO (2011)20 ACOG (2013)14 SOGC (2014)*,19
Previous hypertensive disease  
during a pregnancy*
Previous preeclampsia Previous preeclampsia Previous preeclampsia
Chronic kidney disease Renal disease Chronic renal disease Preexisting renal disease
Autoimmune disease (including SLE/APS) Autoimmune disease SLe APS
Type 1 or type 2 diabetes Preexisting diabetes mellitus Preexisting diabetes mellitus Preexisting diabetes mellitus
Chronic hypertension Chronic hypertension Chronic hypertension Preexisting hypertension
Multiple pregnancy Multiple pregnancy Multiple pregnancy Multiple pregnancy
Nulliparity  Primiparity First ongoing pregnancy (nulliparity)
Age 40 years or older  Age 40 years or older Maternal age $40 years
Pregnancy interval of more than 10 years   inter-pregnancy interval $10 years
Body mass index of $35 kg/m² at booking  Obesity Overweight/obesity
Family history of preeclampsia Family history of preeclampsia Family history of preeclampsia
Family history of early-onset 
cardiovascular disease
Lower maternal birthweight and/or 
preterm delivery
History of thrombophilia Heritable thrombophilias (factor v 
Leiden/protein S deficiency)
increased pre-pregnancy 
triglycerides
Non-smoking
Cocaine and methamphetamine
Previous miscarriage at #10 weeks 
with same partner
New partner
Short duration of sexual 
relationship with current partner
in vitro fertilization Reproductive technologies
Booking SBP $130 mmHg, or  
DBP $80 mmHg
vaginal bleeding in early pregnancy
Gestational trophoblastic disease
Note: *women are at increased risk if they have one of the risk factors in bold or $2 of the other risk factors.
Abbreviations: NiCe, National institute for Health and Care excellence; wHO, world Health Organization; ACOG, American College of Obstetricians and Gynecologists; 
SOGC, Society of Obstetricians and Gynecologists of Canada; SLe, systemic lupus erythematosus; APS, anti-phospholipid antibody syndrome; SBP, systolic blood pressure; 
DBP, diastolic blood pressure.
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resolution of the disease. The challenges of management 
are in balancing the maternal risks of continuing pregnancy 
against the maternal risks of intervention and the fetal risks 
of preterm delivery.
It is important to recognize that, although most guide-
lines include specific gestational cutoffs for expectant and 
interventional management, a continuum of risk exists. 
While opting to continue pregnancy, the goals of treatment 
are to maintain a safe blood pressure, monitor the mother 
for deteriorating disease and the fetus for signs of placental 
dysfunction and growth restriction.
inpatient or outpatient management
ISSHP recommends admitting all women at diagnosis of 
preeclampsia15 to complete a full maternal and fetal assess-
ment, stabilize blood pressure, and finalize a plan of care 
prior to considering outpatient follow-up and management. 
This is also recommended in the Pre-eclampsia Community 
Guideline (PRECOG) day-assessment unit guideline in use in 
the UK, which also lays out suggested investigation pathways 
for women with hypertension but not yet diagnosed with 
preeclampsia,46 and in the WHO20 and ACOG14 guidelines.
At diagnosis of preeclampsia, all women should be 
offered admission to hospital and ultrasound assessment 
of fetal well-being and Doppler studies of the umbilical 
artery performed. While an inpatient, women should have 
their risk of VTE assessed. The combination of pregnancy, 
preeclampsia and inpatient admission significantly increase 
the risk of VTE, so most patients should receive low 
molecular weight heparin for thromboprophylaxis, unless 
they have contraindications. All patients should have a full 
blood count, coagulation profile, and renal and liver func-
tion checked. Uric acid may be of benefit in confirming a 
diagnosis but is not related to maternal or fetal outcome, 
and a normal result does not rule out preeclampsia.47
If blood pressure is persistently elevated (cutoff 
150/100 mmHg), consideration should be given to the com-
mencement of antihypertensive therapy.18 During admission, 
blood pressure should be checked at least 4-hourly, and a 
24-hour urine collection for quantification of proteinuria 
should be performed if not already completed. It is reason-
able to commence treatment on the basis of dipstick or PCR 
results, but a 24-hour urine collection is the gold standard 
for confirming the presence of proteinuria.
Women with stable blood pressure on treatment, normal 
laboratory studies, no concern about fetal well-being, and 
a good understanding of their condition are candidates for 
outpatient management. Outpatient management should be 
undertaken in the context of a specialized day-assessment 
unit and extensive patient briefing on symptoms and signs 
that should prompt urgent presentation to hospital ser-
vices  (headache, abdominal pain, or vaginal bleeding) is 
necessary.
Maternal monitoring should include regular blood pres-
sure measurement in a dedicated day-assessment unit. No 
subsequent quantification of proteinuria is necessary after 
significant proteinuria has been confirmed. Laboratory tests 
of biochemical and hematological parameters should be 
repeated 2–3 times a week, according to the severity and the 
progression of the disease.17
Fetal monitoring
All women diagnosed with preeclampsia should have 
ultrasound assessment of fetal growth, liquor volume, and 
umbilical artery Doppler. As long as pregnancy continues, 
scans should be repeated at fortnightly intervals.18
Mothers should be informed of the importance of self-
monitoring of fetal movement and where to present if there 
are subjectively reduced fetal movements. There is no specific 
evidence related to kick charts or equivalent monitoring 
tools in preeclampsia, and as these women are at high risk 
of placental insufficiency it would be reasonable to perform 
ultrasound assessment at the first presentation with subjec-
tively reduced fetal movement.
Lifestyle modification and patient 
education
There is no evidence to support the use of bed rest in 
the hypertensive disorders of pregnancy, and there is 
a probable harm from reduced mobility increasing the 
risk of thrombosis, infection, and psychosocial harm.48 
Women with preeclampsia should be offered advice on a 
healthy diet and light exercise, as for any other pregnant 
woman.
According to NICE guidance, patients should have their 
diagnosis explained to them clearly, the warning signs of 
progressive disease explained, and the appropriate contact 
points documented in the maternity notes.
Antihypertensive therapy
Antihypertensive therapy aims to reduce the risk of severe 
hypertension and cerebrovascular accidents, cardiovascu-
lar strain, and renal injury. The degree of hypertension at 
which to institute therapy is the subject of controversy. 
NICE guidance recommends commencing therapy when 
blood pressure exceeds 150/100 mmHg, with the aim 
 
In
te
gr
at
ed
 B
lo
od
 P
re
ss
ur
e 
Co
nt
ro
l d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
82
.5
0.
2 
on
 2
2-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
integrated Blood Pressure Control 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Townsend et al
Table 5 Antihypertensive drugs used in pregnancy and lactation
Atenolol Captopril Enalapril Labetalol Methyldopa Hydralazine Nifedipine
Mechanism Beta blocker ACe inhibitor ACe inhibitor Beta blocker Alpha 2 agonist vasodilator Calcium channel blocker
Pregnancy Avoid in first and second trimester. Associated  
with fetal growth restriction and bradycardia,  
reduces uteroplacental blood flow
No – associated with severe fetal  
anomaly, fetal nephropathy, and  
intrauterine death
No – associated with severe  
fetal anomaly, fetal nephropathy, 
and intrauterine death
Yes. Can be given intravenously  
for rapid control of severe  
resistant hypertension
Yes, including first  
trimester. Longest  
post-marketing  
surveillance data
Used intravenously for rapid blood  
pressure control. May be associated  
with neonatal thrombocytopenia. Long  
history of use. Avoid rapid intravenous  
bolus because of risk of hypotension
After 20 weeks. Available in short acting  
forms for rapid blood pressure control  
and long acting for long-term maintenance 
therapy. May be used simultaneously with  
magnesium sulfate. May inhibit labor
Breast-feeding No known evidence of harm (NiCe).  
Second line after labetalol
Manufacturers advise avoid;  
however recommended by SOGC.  
No known evidence of harm (NiCe)
Not for preterm infants. No  
known evidence of harm (NiCe) 
Particularly for women needing  
cardiac/renal protection
Manufacturers recommend  
avoid. very small amounts  
in breast milk. No known  
evidence of harm (NiCe)
No known evidence  
of harm (NiCe)
excreted in breast milk, at levels too  
low to be harmful
Manufacturers advise avoid, no known  
evidence of harm (NiCe). Amounts in  
breast milk too small to be harmful. 
Second line: Amlodipine
Postnatal Yes Yes Yes Yes NiCe says avoid Yes Yes
Side-effects Risk of fetal growth restriction  
and bradycardia in pregnancy
Cough Cough Tachycardia Depression Headache
Reduced variability on CTG
Methyldopa hepatitis
Contraindications Asthma Asthma Mental health disorders
Hepatic disease
Abbreviations: ACe, angiotensin-converting enzyme; CTG, cardiotocography; NiCe, National institute for Health and Care excellence; SOGC, Society of Obstetricians 
and Gynecologists of Canada.
of maintaining blood pressure below this level, and the 
SOGC guidelines are similar.19 This is stressed in the 
Top 10 recommendations of the most recent CMACE 
report.4 Based on a review of maternal deaths in the UK, 
the authors stress that systolic hypertension should be 
treated seriously and that failure to do so was a feature 
of several maternal deaths from cerebral hemorrhage and 
aortic dissection.4
The ACOG guidelines are more conservative, citing 
concerns about the side-effects of antihypertensive therapy 
in pregnancy and the relative rarity of complications at blood 
pressures of 150/100 mmHg, and would recommend treat-
ment only for blood pressure over 160/110 mmHg.14 The 
WHO guideline specified that the evidence is not yet suffi-
cient to determine which strategy is preferable, but ongoing 
study will clarify this issue in the near future.20 In all cases, 
care should be taken to avoid reducing the blood pressure 
below the lower limits (110/80 mmHg) which would lead to 
a risk of placental underperfusion.15
Choice of antihypertensive in moderate 
hypertension
NICE recommends that the first line antihypertensive 
should be labetalol. However, there is insufficient evidence 
as to which antihypertensive is most effective.49  Acceptable 
and commonly used alternatives are methyldopa and 
nifedipine.
There is some evidence outside of pregnancy that beta 
blockers are less effective in controlling hypertension in 
Afro-Caribbean patients, who may have elevated renin levels 
even at a young age.50 This leads some to argue that, as these 
patients are likely to be resistant to labetalol, nifedipine 
should be the first line drug for them. Nifedipine may be 
more effective in controlling blood pressure than labetalol or 
hydralazine, but labetalol was associated with fewer adverse 
perinatal events, and remains generally the recommended 
first line antihypertensive.51
Angiotensin-converting enzyme (ACE) inhibitors and 
alpha blockers are not appropriate in pregnancy. Choice 
of antihypertensive should be guided by an individualized 
assessment of the patient and risk of adverse reactions. Mul-
tiple medications may be needed in women with persistent 
severe hypertension at the maximal dose of their first line 
antihypertensive. Table 5 outlines the commonly used anti-
hypertensive drugs in the UK.
Treatment of severe disease
Severe hypertension
Severe hypertension (.160–170/100–110 mmHg) requires 
antihypertensive treatment. In the absence of symptoms sug-
gestive of impending eclampsia it is reasonable to start with 
oral therapy, if tolerated by the mother. It can be a feature of 
essential or gestational hypertension, but may also represent 
progression to full preeclampsia. The patient should undergo a 
full evaluation, including urine and blood tests, to detect new 
onset preeclampsia. A systolic blood pressure of .180 mmHg 
is a medical emergency and should be controlled rapidly with 
intravenous antihypertensives. A maintenance infusion may be 
required. An important principle is to avoid causing relative 
hypotension and compromising uteroplacental circulation 
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Table 5 Antihypertensive drugs used in pregnancy and lactation
Atenolol Captopril Enalapril Labetalol Methyldopa Hydralazine Nifedipine
Mechanism Beta blocker ACe inhibitor ACe inhibitor Beta blocker Alpha 2 agonist vasodilator Calcium channel blocker
Pregnancy Avoid in first and second trimester. Associated  
with fetal growth restriction and bradycardia,  
reduces uteroplacental blood flow
No – associated with severe fetal  
anomaly, fetal nephropathy, and  
intrauterine death
No – associated with severe  
fetal anomaly, fetal nephropathy, 
and intrauterine death
Yes. Can be given intravenously  
for rapid control of severe  
resistant hypertension
Yes, including first  
trimester. Longest  
post-marketing  
surveillance data
Used intravenously for rapid blood  
pressure control. May be associated  
with neonatal thrombocytopenia. Long  
history of use. Avoid rapid intravenous  
bolus because of risk of hypotension
After 20 weeks. Available in short acting  
forms for rapid blood pressure control  
and long acting for long-term maintenance 
therapy. May be used simultaneously with  
magnesium sulfate. May inhibit labor
Breast-feeding No known evidence of harm (NiCe).  
Second line after labetalol
Manufacturers advise avoid;  
however recommended by SOGC.  
No known evidence of harm (NiCe)
Not for preterm infants. No  
known evidence of harm (NiCe) 
Particularly for women needing  
cardiac/renal protection
Manufacturers recommend  
avoid. very small amounts  
in breast milk. No known  
evidence of harm (NiCe)
No known evidence  
of harm (NiCe)
excreted in breast milk, at levels too  
low to be harmful
Manufacturers advise avoid, no known  
evidence of harm (NiCe). Amounts in  
breast milk too small to be harmful. 
Second line: Amlodipine
Postnatal Yes Yes Yes Yes NiCe says avoid Yes Yes
Side-effects Risk of fetal growth restriction  
and bradycardia in pregnancy
Cough Cough Tachycardia Depression Headache
Reduced variability on CTG
Methyldopa hepatitis
Contraindications Asthma Asthma Mental health disorders
Hepatic disease
Abbreviations: ACe, angiotensin-converting enzyme; CTG, cardiotocography; NiCe, National institute for Health and Care excellence; SOGC, Society of Obstetricians 
and Gynecologists of Canada.
while still reducing the blood pressure to a level not associated 
with cerebral adverse events. The target of treatment should 
be to maintain blood pressure at ,150/100 mmHg.
Oral fast acting nifedipine, intravenous hydralazine, and 
labetalol are equally efficient for management of acute severe 
hypertension in pregnancy, so the choice should be guided 
by local protocols, clinician familiarity, and individualized 
patient risk profiles.48
Blood pressure should be checked at least every 5 minutes 
while attempting to gain control, and if refractory consid-
eration should be given to invasive monitoring. All women 
with severe hypertension should be managed in a minimum 
of a level 2 care bed until stable, whether or not management 
includes delivery.
Severe preeclampsia
Women with severe preeclampsia (as defined by the national 
guidelines described in Table 1) should be managed as 
inpatients with senior clinicians reviewing the plan of care 
on a daily basis. Before 34 weeks, the focus of care is on 
prolonging pregnancy as long as the mother is stable, in the 
interests of the fetus. Where some would advocate deliv-
ery within 24–48 hours of diagnosis of early onset stable 
severe preeclampsia (interventionist management), doing so 
increases neonatal morbidity with no proven maternal benefit. 
It is instead common practice to continue pregnancy until 
maternal condition cannot be stabilized safely  (expectant 
management).52 Since delivery may become necessary rap-
idly, corticosteroids for fetal lung maturity should be con-
sidered at the diagnosis of severe early onset preeclampsia. 
Women meeting the criteria for delivery would normally also 
merit treatment with magnesium sulfate.
Women who meet the criteria for the diagnosis of severe 
preeclampsia (Table 1) or have significant signs and symp-
toms of impending eclampsia (severe headache, clonus, 
neurological impairment) should be considered for treat-
ment with magnesium sulfate for eclampsia prophylaxis. 
 Magnesium sulfate is associated with a 50%–67% reduction 
in the risk of seizures, a reduction in the risk of maternal 
death, and may have some benefit to the baby.53 The stan-
dard protocol is as described in the Collaborative Eclampsia 
Trial,54 a 4 g loading dose with a maintenance infusion of 1 
g/h.  Treatment with magnesium sulfate requires at least level 
2 care, with close monitoring, observation of urine output, 
respiratory rate, and deep tendon reflexes. After 34 weeks, 
the decision to deliver should be based on the condition of 
the mother and baby and any identifiable risk factors for 
progression of disease.
eclampsia
Eclampsia is an obstetric emergency, and the first priority is to 
stabilize the mother through the application of a standardized 
ABCDE (airway, breathing, circulation, disability and evalu-
ate) approach. Most eclamptic seizures are self-terminating; 
however, magnesium sulfate should be commenced as soon as 
possible if not already in progress, according to the protocol 
described above. If magnesium sulfate therapy has already 
commenced, a further bolus may be given, and the mainte-
nance infusion may be increased to 2 g/h.54 Hypertension 
should be controlled as outlined above, and the intravenous 
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route is preferable as the mother is likely to be in a state of 
altered consciousness. Recurrent seizures may warrant intu-
bation and paralysis in order to maintain oxygenation.
Fetal monitoring is not a priority until the mother has been 
stabilized. Auscultation or cardiotocography will inevitably 
show a fetal bradycardia during and immediately after a 
seizure, but the primary interventions are seizure and blood 
pressure control, not delivery.
As soon as the mother’s condition is judged stable she 
should be delivered by the most expedient route. In certain 
selected situations this may be achievable vaginally, but will 
most commonly be by Cesarean section. All women who 
have suffered an eclamptic seizure should be cared for in a 
level 3 setting.
Timing of delivery
The only cure for preeclampsia is delivery of the placenta, and 
all other management merely serves to stabilize the mother 
and enable the extension of pregnancy in the interests of the 
fetus. The timing of delivery is therefore guided by weighing 
the relative risks of preterm delivery to the fetus against the 
risks of continuing the pregnancy to the mother.
At any gestation, delivery is indicated for life-threatening 
maternal disease, which may take the form of severe refrac-
tory hypertension, eclampsia, placental abruption or rapidly 
deteriorating HELLP syndrome, or renal dysfunction. After 
the age of viability, delivery may also be indicated for serious 
fetal compromise with preterminal Doppler or CTG changes. 
If this is the primary indication for delivery at 24–26 weeks, 
a frank discussion with the parents regarding the poor prog-
nosis for the baby, particularly in the setting of marked intra-
uterine growth restriction, and the potential complications of 
preterm surgery, should be had before proceeding.
In all cases the mother should be stabilized before 
proceeding to delivery. Performing a category 1 Cesarean 
section immediately after an eclamptic seizure without full 
assessment of the mother and baby exposes her to severe risks 
associated with general anesthetic (failed intubation, severe 
hypertension, aspiration, further cerebral event), bleeding 
secondary to an undetected coagulopathy, and rushed, poten-
tially complex, surgery with a higher risk of intraoperative 
damage to bladder and ureters. Once the mother is stable, 
any blood products ordered and the appropriate obstetric, 
anesthetic and neonatal team assembled, delivery can be 
accomplished safely, if it is indicated. If the patient is sig-
nificantly preterm (,34 weeks) and delivery could be safely 
postponed for 12–24 hours, consideration should be given to 
the administration of corticosteroids for lung maturity.18
In the presence of stable disease without severe features 
before 34 weeks, delivery should not be undertaken. Between 
34 and 37 weeks any features of worsening disease should 
prompt thorough review of the clinical case and consideration 
of delivery.
A clinical test to identify those women most at risk of 
serious adverse events in continued pregnancy would be 
invaluable to reduce the number of unnecessary preterm 
deliveries. Two models have recently been developed that 
may identify this group of patients. The fullPIERS model 
incorporates gestational age, chest pain or dyspnea, SpO
2
, 
platelet count, creatinine, and aspartate transaminase and 
predicts adverse maternal outcomes within 48 hours and 7 
days with an AUC (area under the curve) of 0.88 and .0.7 
respectively.55 This model has undergone external validation56 
and seems to perform well as a prediction tool but has not 
yet been tested in a clinical context as a decision making 
aid. A similar model has been developed in the context of 
low resource clinical settings incorporating physical findings 
and symptoms rather than the more specialized laboratory 
tests in the fullPIERS. The features included are parity, ges-
tational age, systolic blood pressure, degree of proteinuria, 
vaginal bleeding with abdominal pain, headache and/or 
visual changes, and chest pain and/or dyspnea.57 Predictive 
modeling along these lines may be improved in the future by 
the addition of biochemical or ultrasound markers and offer 
a significant opportunity for targeting intervention in a way 
that can optimize maternal and fetal outcomes.
Delivery need not be by Cesarean section if assessment 
shows a possibility of successful induction of labor with 
cervical ripening agents. Over half of all inductions before 
35 weeks end in Cesarean section, and it would be inappro-
priate to continue an induction for 2–3 days in the presence 
of severe disease warranting delivery. However sometimes a 
vaginal delivery is achievable rapidly and may be preferable 
than the additional risks of bleeding, thrombosis, infection, 
and fluid management challenges associated with operative 
delivery.
After 37 weeks, any woman with gestational hypertension 
or mild to moderate disease should have delivery discussed 
with her. The HYPITAT58 trial demonstrated that induction 
of labor at this gestation reduces the risk of adverse mater-
nal events and carries no additional risk to the neonate. In 
addition, this strategy does not seem to increase the risk of 
Cesarean section, and the women most likely to benefit are 
those least favorable for induction.
The trial was conducted in a setting where women are 
not treated for hypertension ,160/100 at term, and may 
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not be directly applicable to the UK population where 
antihypertensive therapy is offered for lower degrees of 
hypertension, as one of the outcomes was the occurrence 
of severe hypertension. It is also reasonable to offer anti-
hypertensive treatment and continue pregnancy under close 
monitoring as long as blood pressure is controlled and there 
are no features of severe disease if that is the woman’s wish.18 
This should be clearly explained to the woman and, if she 
chooses to continue the pregnancy she should be offered 
regular follow-up in the hospital day-assessment unit, as 
outlined above, with regular fetal assessment, and a clear plan 
of care made for when induction of labor will be planned if 
no spontaneous labor has occurred.
Intrapartum care
Women with gestational hypertension or preeclampsia of 
any severity have a higher risk of placental insufficiency 
and subsequent fetal hypoxic stress during labor secondary 
to poor placental reserves. For this reason all women with 
hypertensive disorders in pregnancy should be advised to 
have continuous fetal monitoring in labor. Blood pressure 
should be measured hourly in labor, and any antihypertensive 
medication continued as previously prescribed. In women 
with severe preeclampsia, more frequent blood pressure 
measurement is required and consideration should be given 
to invasive monitoring, particularly if intravenous antihyper-
tensive therapy is required.
An anesthetist should review every woman with hyper-
tensive disease admitted in labor to assess her airway and 
make a contingency plan for emergencies. Early epidural 
or spinal analgesia reduces the risk of needing a general 
anesthetic for emergency intervention. Pharyngolaryngeal 
edema in preeclamptic patients increases the chances of 
failed intubation, and intubation increases the chances of 
severe hypertension and aspiration. Women with hypertensive 
disorders should not routinely receive a fluid preload prior to 
initiating epidural or spinal analgesia.18 Consideration should 
be given to the potential need for blood products based on 
the hematological and coagulation parameters as measured at 
the onset of labor. If platelets are ,50×109/L, falling rapidly, 
or there is associated coagulopathy, consideration should be 
given to ordering platelets and other blood products. Platelet 
transfusion is required if platelets fall below 20×109/L around 
delivery, whatever the mechanism. There is no indication to 
limit the length of the second stage if the blood pressure is 
stable and well controlled. However, in the event of severe 
uncontrolled hypertension or neurological symptoms, elec-
tive instrumental delivery may be recommended.
Ergometrine and oxytocin are in common use as 
uterotonics for the active management of the third stage of 
labor. However, ergometrine should be avoided for women 
with known hypertensive disease of any kind, even if blood 
pressure is normal at the time of delivery. Several maternal 
deaths have been provoked by the hypertension associated 
with ergometrine use.4 This should not preclude the use of 
ergometrine in the event of severe postpartum hemorrhage 
at the discretion of senior clinical staff.
Postnatal care
Although delivery is the cure for preeclampsia and the related 
disorders, resolution is not immediate and many women 
may initially deteriorate after delivery, or re-present some 
days later with worsening disease. Women being managed 
in Level 2 or 3 care should be maintained there for at least 
24 hours postpartum, and magnesium sulfate that has been 
commenced prior to delivery should be continued to 24 hours 
postdelivery.
Postpartum hypertension
In normal pregnancy, blood pressure falls immediately post-
delivery and peaks 3–6 days postdelivery. In hypertensive 
women this is also the case, and women frequently experience 
a further spike in their blood pressure several days postpar-
tum. In fact, 32%–44% of all eclampsia occurs postpartum.59 
Preeclampsia can present for the first time postpartum, and 
for that reason blood pressure measurement should continue 
to be part of the full postnatal check for all women, regardless 
of their history in pregnancy. There is no benefit in routine 
testing of urine for proteinuria because of the inevitable 
contamination of the urine with lochia that will render the 
results uninterpretable. If a woman with no previous history 
of preeclampsia presents with hypertension and other features 
of disease, a catheter specimen of urine for dipstick or PCR 
may be of limited use in establishing a diagnosis.
Other factors that can cause or exacerbate hyperten-
sion postpartum are pain, anxiety, the use of certain drugs 
(nonsteroidal anti-inflammatory drugs [NSAIDS], and 
 ergometrine), and fluid overload in labor. These factors 
should be assessed and analgesia and fluid management 
adjusted as necessary prior to altering antihypertensive 
management. NSAIDs should be avoided in women with 
known hypertensive disease because of the risk of exacerbat-
ing both hypertension and any renal injury.
The same targets for control of hypertension apply as in 
pregnancy – the aim should be to control the blood pressure 
at less than 150/100 mmHg if on medication. If any new 
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features of severe disease develop, mothers should be moved 
to a higher level of care and consideration given to adminis-
tering at least 24 hours of magnesium sulfate as eclampsia 
prophylaxis. Any woman with a new onset severe headache, 
with or without neurological symptoms, should be assessed 
to evaluate the possibility of postpartum stroke or venous 
thrombosis.
Choice of antihypertensive
No antihypertensive drugs are licensed for use in breast-
feeding, so most evidence is based on observational stud-
ies and expert opinion. In addition to the drugs used in 
pregnancy, the ACE inhibitors Enalapril and Captopril have 
been shown to be safe and effective in breast-feeding women 
(Table 5). They are particularly appropriate for women need-
ing renal or cardiac protection because of their pre-pregnancy 
comorbidities.
Methyldopa is the drug of choice for the Medicines and 
Healthcare Products Regulatory Agency (MHRA) because 
of a long history of use, but is usually avoided by clinicians 
because of its side-effect profile, including depression and 
sedation, as recommended by NICE.17
Outpatient management
If the blood pressure is stable and well controlled, and there 
are no other features of severe disease women may be dis-
charged to community care. For the 1st week, blood pressure 
should be checked at least every other day, and then weekly. 
The antihypertensive medication can be reduced and then 
stopped by the primary care provider when target blood 
pressures are achieved.
For most women, hypertension will resolve within the 
1st week postpartum.60 Hypertension that persists more 
than 6 weeks postpartum usually represents a pathology not 
directly associated with pregnancy such as essential hyperten-
sion or underlying endocrine, neurological, or renal disease. 
These women should have their hypertension confirmed 
with ambulatory monitoring and referred for investigation 
for a secondary cause for their hypertension as suggested in 
the guidelines for new onset hypertension in young adults. 
Proteinuria that persists beyond 6–12 weeks postpartum may 
also warrant further investigation, particularly in the setting 
of early onset preeclampsia, the group of women most likely 
to have underlying renal disease.
Future health risks and screening
All women who have had a hypertensive complication in 
pregnancy should receive postnatal counseling regard-
ing the management of future pregnancies. For women 
with gestational hypertension, the risk of recurrence of 
hypertension in the next pregnancy is 16%–47% and the risk 
of preeclampsia is 2%–7%. For women with preeclampsia, 
the risk of recurrence is 16% if they delivered at term, 25% 
if they delivered before 34 weeks, and 55% if they delivered 
before 28 weeks.59
These women should be advised to book early in their 
next pregnancy for consideration of starting low-dose aspirin 
as prophylaxis against preeclampsia. They should also have 
more frequent blood pressure and urine dipstick monitoring 
in pregnancy, particularly approaching the gestation at which 
symptoms commenced in the index pregnancy. Women on 
long-term antihypertensive therapy should be counseled to 
stabilize blood pressure on medications safe to use in the first 
trimester, prior to attempting to conceive.
Women who have had preeclampsia and delivered before 
34 weeks should be screened for antiphospholipid syndrome.18 
All women who have had any element of hypertensive disease 
in pregnancy or the puerperium have an increased risk of 
cardiovascular disease in the future. The associated adverse 
outcomes demonstrated by meta-analysis are increased risk of 
cardiovascular disease, chronic hypertension, venous throm-
boembolism, and cerebrovascular disease.9–12
The obstetric team at discharge and the primary care 
physician in the community have an opportunity to counsel 
women at this point about their future risk and offer simple 
lifestyle modification suggestions to help reduce future risk. 
Weight loss, smoking cessation, low salt, and regular exercise 
may be recommended as a matter of common sense.  However, 
no evidence yet exists that these measures can improve long-
term outcomes in these women.
In conclusion, this review presents the current best prac-
tice in diagnosis and management of preeclampsia. New 
tools for early detection, prevention, and management of 
preeclampsia have the potential to revolutionize practice in 
the coming years.
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